Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 16;44(1):179.
doi: 10.1007/s10792-024-03117-6.

Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study

Chaeyeon Lee  1 , Ji Woong Park  2 , Yoon-Duck Kim  3 , Kyung In Woo  4
Affiliations

Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study

Chaeyeon Lee et al. Int Ophthalmol. .

Abstract

Purpose: To evaluate the clinical outcomes of intravenous tocilizumab (TCZ) injection in patients with moderate-to-severe active thyroid eye disease (TED).

Methods: Patients with active and moderate-to-severe TED who did not respond to conventional therapies were treated with TCZ from June 2019 to January 2021. The medical records of the patients were evaluated before the treatment. We analyzed patient demographics, including the duration of Graves' disease and TED, and assessed subjective symptoms, such as diplopia and ocular movement, clinical activity score (CAS), modified NOSPECS score, and exophthalmos before treatment and at 4, 8, 12, and 16 weeks after the first drug injection. Blood tests, including TSH Rc Ab and TS Ab, were performed before treatment and 24 weeks after the first injection. And orbital computed tomography (CT) was performed and Barrett's Index was calculated at baseline and after completion of all injections.

Results: Nineteen completed the scheduled treatment. There were no significant side effects, other than herpes zoster in one case and headache and dermatitis in another. Clinical symptoms before and 16 weeks after the treatment showed mean CAS decreased by 2.4 points, mean modified NOSPECS score decreased by 3.7 points, and mean exophthalmos decreased by 0.4 mm. Diplopia and extraocular muscle limitation improved in ten and remained stationary in five of the 15 patients, who presented with extraocular motility abnormalities. Six of 11 patients who underwent orbit CT showed improvement in muscle size. The mean TSH Rc Ab decreased by 7.5 IU/L and TS-Ab decreased by 162.9%.

Conclusion: TCZ can treat active moderate-to-severe TED, showing high drug compliance and reasonable response to inflammation and extraocular motility abnormality.

Keywords: Efficacy; Intravenous injection; Thyroid eye disease; Tocilizumab.

PubMed Disclaimer

References

    1. Woo KI, Kim YD, Lee SL (2008) The clinical characteristics of thyroid orbitopathy in thyroid dysfunction patients in korea. J Korean Ophthalmol Soc 49:1387–1396. https://doi.org/10.3341/jkos.2008.49.9.1387 - DOI
    1. Perros P, Neoh C, Dickinson J (2009) Thyroid eye disease. BMJ 338:b560. https://doi.org/10.1136/bmj.b560 - DOI - PubMed
    1. Woo KI, Kim YD, Lee SY (2013) Prevalence and risk factors for thyroid eye disease among Korean dysthyroid patients. Korean J Ophthalmol 27:397–404. https://doi.org/10.3341/kjo.2013.27.6.397 - DOI - PubMed - PMC
    1. Crisp M, Starkey KJ, Lane C, Ham J, Ludgate M (2000) Adipogenesis in thyroid eye disease. Invest Ophthalmol Vis Sci 41:3249–3255 - PubMed
    1. Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D (2016) Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol 100:142–150. https://doi.org/10.1136/bjophthalmol-2015-307399 - DOI - PubMed

LinkOut - more resources